大行評級丨摩根大通:下調奈飛評級至“中性” 剔出美股分析師焦點名單
摩根大通發表報告,下調對奈飛的投資評級,由“增持”降至“中性”,基於顯著的股價上升及跑贏大市,相信該股風險回報已變得更爲平衡。該行將奈飛剔出美股分析師焦點名單,目標價則由1150美元上調至1220美元,相當於預測明年市盈率40倍及明年每股自由現金流預測45倍。
該行指,奈飛股價正處歷史高位,相當於明年預測市盈率39倍明年每股自由現金流預測44倍,可能已反映2025年指引上望空間。該股亦被視爲防守股,但若關稅及宏觀憂慮持續紓緩,預期資金流向其他科網股及其他表現落後股份。該行亦指,夏季爲季節性公司增長較慢月份,繼《Upfront》推出後,短期催化劑或較少,縱使第三季節目內容吸引。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.